PCSK9 and myocardial infarction: In clinical trials, the use of PCSK9 inhibitors in patients with recent myocardial infarction demonstrated a benefit over a treatment period of 3 years,21 without major adverse events, even in those who attained very low LDL‐C levels with evolocumab (< 20 mg/dL).15, 22